DE69706825D1 - Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen - Google Patents

Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Info

Publication number
DE69706825D1
DE69706825D1 DE69706825T DE69706825T DE69706825D1 DE 69706825 D1 DE69706825 D1 DE 69706825D1 DE 69706825 T DE69706825 T DE 69706825T DE 69706825 T DE69706825 T DE 69706825T DE 69706825 D1 DE69706825 D1 DE 69706825D1
Authority
DE
Germany
Prior art keywords
papillomavirus
pharmaceutical composition
infections caused
composition against
against tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69706825T
Other languages
English (en)
Other versions
DE69706825T2 (de
DE69706825T3 (de
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69706825(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of DE69706825D1 publication Critical patent/DE69706825D1/de
Publication of DE69706825T2 publication Critical patent/DE69706825T2/de
Publication of DE69706825T3 publication Critical patent/DE69706825T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DE69706825T 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen Expired - Lifetime DE69706825T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
FR9609584 1996-07-30
PCT/FR1997/001412 WO1998004705A1 (fr) 1996-07-30 1997-07-29 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (3)

Publication Number Publication Date
DE69706825D1 true DE69706825D1 (de) 2001-10-25
DE69706825T2 DE69706825T2 (de) 2002-05-02
DE69706825T3 DE69706825T3 (de) 2006-08-24

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Country Status (12)

Country Link
EP (2) EP1149910B1 (de)
JP (2) JP4070815B2 (de)
AT (2) ATE205881T1 (de)
AU (1) AU736720B2 (de)
CA (1) CA2234263C (de)
DE (2) DE69728914T2 (de)
DK (2) DK1149910T3 (de)
ES (2) ES2215805T3 (de)
FR (1) FR2751879B1 (de)
HK (1) HK1043809B (de)
PT (2) PT862634E (de)
WO (1) WO1998004705A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2335506A1 (en) * 1998-06-26 2000-01-06 Aventis Pasteur Mucosal targeting immunisation
DK2530161T3 (en) * 2006-06-20 2018-06-06 Transgene Sa Process for the preparation of poxviruses and poxvirus compositions
BRPI1006901A2 (pt) 2009-01-20 2016-02-16 Transgène S A método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangue
HUE026194T2 (en) 2009-03-24 2016-05-30 Transgene Sa Biomarker for checking patients
RU2555340C2 (ru) 2009-04-17 2015-07-10 Трансжене Са Биомаркер для мониторинга пациентов
CA2761457A1 (en) 2009-05-12 2010-11-18 Transgene Sa Immortalized avian cell lines and use thereof
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
SG178090A1 (en) 2009-07-21 2012-03-29 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX2017007178A (es) 2014-12-01 2017-08-28 Transgene Sa Formulaciones liquidas estables de virus de vacuna.
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
KR20200003921A (ko) 2017-05-15 2020-01-10 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스-함유 조성물
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
AU650868B2 (en) † 1990-03-20 1994-07-07 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000019I1 (de) * 1991-07-19 2007-07-26 Univ Queensland Impfstoffen gegen Papillomavirus
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
HK1043809B (zh) 2004-12-03
PT862634E (pt) 2002-03-28
DK1149910T3 (da) 2004-08-02
DE69728914D1 (de) 2004-06-03
JP4198735B2 (ja) 2008-12-17
EP0862634B1 (de) 2001-09-19
JP4070815B2 (ja) 2008-04-02
ES2163795T3 (es) 2002-02-01
DE69728914T2 (de) 2005-04-07
CA2234263C (fr) 2009-10-13
FR2751879B1 (fr) 1998-10-30
ES2215805T3 (es) 2004-10-16
WO1998004705A1 (fr) 1998-02-05
JP2007254474A (ja) 2007-10-04
AU736720B2 (en) 2001-08-02
EP0862634A1 (de) 1998-09-09
AU3855297A (en) 1998-02-20
CA2234263A1 (fr) 1998-02-05
EP1149910A1 (de) 2001-10-31
EP1149910B1 (de) 2004-04-28
EP0862634B2 (de) 2006-03-01
DE69706825T2 (de) 2002-05-02
DE69706825T3 (de) 2006-08-24
DK0862634T3 (da) 2002-01-21
ATE205881T1 (de) 2001-10-15
DK0862634T4 (da) 2006-05-08
HK1043809A1 (en) 2002-09-27
PT1149910E (pt) 2004-09-30
JP2000500662A (ja) 2000-01-25
ATE265535T1 (de) 2004-05-15
FR2751879A1 (fr) 1998-02-06
ES2163795T5 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
SE9504661D0 (sv) New compounds
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE59205752D1 (de) Substituierte Biphenylpyridone als Angiotensin II Antagonisten
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
FI891361A (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
ATE221059T1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
UA50808C2 (uk) Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
CA2111083A1 (en) Novel peptides, their preparation and use
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
SE9504662D0 (sv) New compounds
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
GEP20022840B (en) Form VI 5,6-Dichloro-2-(Isopropylamino)-1-(Beta-L-Ribofuranosyl-1H-Benzimidazole), Method for Their Production, Composition for Treating Virus Infections and Methods for Treatment
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
YU46302A (sh) Supstituisani piroli

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings